Status:
TERMINATED
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.
Detailed Description
Following review of the preliminary data from completed study A7081004, the development program for CP-741,952 was terminated on 15 March 2007. Primary reasons for program termination included a lack ...
Eligibility Criteria
Inclusion
- BMI of 30-40 kg/m2
Exclusion
- Women of childbearing potential
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00367783
Start Date
June 1 2006
End Date
April 1 2007
Last Update
August 1 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48105
2
Pfizer Investigational Site
Kalamazoo, Michigan, United States, 49007
3
Pfizer Investigational Site
New York, New York, United States, 10021-7903
4
Pfizer Investigational Site
Charlotte, North Carolina, United States, 28211